Stockscreener 앱 받기
0.00
100.00%
-0.0002
전일 마감가:
$0.0002
열려 있는:
$0
하루 거래량:
0
Relative Volume:
0.00
시가총액:
$N/A
수익:
-
순이익/손실:
$-34.63M
주가수익비율:
0.00
EPS:
-13.08
순현금흐름:
$-29.19M
1주 성능:
-100.00%
1개월 성능:
-96.46%
6개월 성능:
-99.58%
1년 성능:
-99.78%
1일 변동 폭
$0.00
$0.00
1주일 범위
$0.00
$0.00
52주 변동 폭
$0.00
$0.0002
Effector Therapeutics Inc Stock (EFTR) Company Profile
EFTR을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
EFTR
Effector Therapeutics Inc
|
0.00 | 0 | 0 | -34.63M | -29.19M | -13.08 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.45 | 115.69B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
529.24 | 53.25B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
307.99 | 39.22B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
577.89 | 35.78B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
269.63 | 27.68B | 3.81B | -644.79M | -669.77M | -6.24 |
Effector Therapeutics Inc Stock (EFTR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2022-01-25 | 다운그레이드 | Stifel | Buy → Hold |
| 2021-11-09 | 업그레이드 | Stifel | Hold → Buy |
| 2021-10-12 | 개시 | Credit Suisse | Outperform |
| 2021-10-04 | 개시 | Mizuho | Buy |
| 2021-09-21 | 개시 | JMP Securities | Mkt Outperform |
| 2021-09-20 | 개시 | Stifel | Hold |
| 2021-09-13 | 개시 | Cantor Fitzgerald | Overweight |
모두보기
Effector Therapeutics Inc 주식(EFTR)의 최신 뉴스
eFFECTOR Therapeutics Faced Investigation Over Non-Compliance with Nasdaq and Delisting - TradingView
RNA Targeted Therapeutics Market to See Booming Growth - openPR.com
eFFECTOR Therapeutics Reports Positive Interim Results in Zotatifin (eFT226) Phase 1/2 Clinical Trial at ASCO 2022 Showing Safety and Tolerability, and Initial Signals of Clinical Activity - The Globe and Mail
Biopharma Dealmaking Quarterly Statistics, Q2 2013 - insights.citeline.com
eFFECTOR Therapeutics to Present Interim Data from Ongoing Zotatifin Phase 1/2 Dose Escalation and Expansion Trial at 2022 ASCO Annual Meeting - Barchart.com
Tech-Enabled, Human-Centered: TELUS Digital and Ryan Strategic Advisory Reveal New Trust, Safety & Security Priorities for 2025 - The Globe and Mail
The Chlamydia effector Dre1 binds dynactin to reposition host organelles during infection - ScienceDirect.com
PD-L1 Non-small Cell Lung Cancer Treatment Market Size in 7MM - openPR.com
Global Equity Markets Slide on US Tariff Concerns - The Globe and Mail
Marjorie Taylor Greene Is Buying Up Beaten-Down Tesla Stock. Should You? - The Globe and Mail
News: CMN Weekly (28 February 2025)Your Weekly CRISPR Medicine News - CRISPR Medicine News
Your Ford Stock Dividend Could Be at Risk If Trump Goes Ahead with Tariffs - The Globe and Mail
Map Kinase Interacting Serine Protein Kinase 1 Market Enabling Agile and Scalable Business Models in the Digital Age - ExpressVartha
Best Statistical RNA Targeted Therapeutics Market Growth Set - openPR
eFFECTOR Therapeutics (EFTR) Projected to Post Earnings on Friday - Defense World
Exclusive: Atomwise, a once high-flying AI startup, taps biotech vet as CEO to lead pared-down company - Endpoints News
Can Scientists Throw a Wrench into Cancer’s Growth Gears? - WebWire
Sarah Larson, MD, on Evaluating Lyell’s CAR-T IMPT-314 in LBCL - CGTLive®
eFFECTOR Therapeutics (EFTR) to Release Quarterly Earnings on Tuesday - Defense World
Structure Therapeutics selects lead oral DACRA for obesity - BioWorld Online
Colorectal Cancer Therapeutics Market Overall Study Report - openPR
Chronic Venous Ulceration Therapeutics Market in the 7MM is expected to grow by 2034, estimates DelveInsight - The Globe and Mail
The Effector Functions of AntibodiesDaëron2024Immunological Reviews - Wiley Online Library
CERo Therapeutics, Inc. Appoints Chris Ehrlich CEO - GlobeNewswire
BioGene Therapeutics Announces Appointment of Dr. Brian Gallagher, Jr. to Corporate Advisory Board - Newsfile
The 2024 Biotech Graveyard - Fierce Biotech
Non-COVID mRNA Vaccine and Therapeutics Market Expected to Reach $1,684.80 Million by 2031 - WhaTech
mRNA Treatment Market Exclusive Report 2024-2031 - InsightAce Analytic
CERo Therapeutics, Inc. Names Al Kucharchuk Chief Financial Officer and Kristen Pierce Chief Development Officer - GlobeNewswire
Targeted recruitment of immune effector cells for rapid eradication of influenza virus infections - PNAS
UK calls for new long-range effector under ‘Project Brakestop’ - Army Technology
Oncternal Therapeutics Axes B-Cell Lymphoma Trial for CAR-T Therapy ONCT-808 - CGTLive™
Keto diet plus experimental drug may shrink pancreatic tumors - Healio
Tyra Biosciences Appoints Doug Warner, M.D., as Chief Medical Officer - PR Newswire
Cartesian Therapeutics Doses First Patient With mRNA CAR-T Descartes-15 in Trial for R/R Multiple Myeloma - CGTLive™
A Ketogenic Diet Could Improve the Response to Pancreatic Cancer Therapy - UC San Francisco
FORE Biotherapeutics Names Michael Byrnes as Chief Financial Officer - Business Wire
Policy and perspective on outpatient programs for autologous hematopoietic cell transplantation and immune-effector cell therapy administration - Frontiers
3 Publicly Traded Companies Filing for Bankruptcy as July Kicks Off - Yahoo Finance
Two healthcare SPACs go public, with several more on the hunt for deals - Endpoints News
Context Therapeutics Acquires Phase 1-ready T cell Engager CT-95 - GlobeNewswire
StockWatch: Layoffs, ARK Selloff Sink Ginkgo Bioworks - Genetic Engineering and Biotechnology News
Calif. biotech company that raised $325 million shuts down, lays off all workers - SFGATE
EFFECTOR Therapeutics, Inc. Appoints Craig R. Jalbert as CEO - Marketscreener.com
Repair of the Infarcted Heart: Cellular Effectors, Molecular Mechanisms and Therapeutic Opportunities - American Heart Association Journals
Reversible Chemical Modification of Antibody Effector Function Mitigates Unwanted Systemic Immune Activation - ACS Publications
eFFECTOR Therapeutics to Collaborate with the Dana-Farber Cancer Institute on an Investigator-Sponsored Phase 2 Clinical Trial Evaluating Zotatifin as Combination Treatment in ER+ Endometrial Cancer and in Low Grade Serous Ovarian Cancer - GlobeNewswire
eFFECTOR Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewswire
Glis2 is an early effector of polycystin signaling and a target for therapy in polycystic kidney disease - Nature
Blockade of TGF-β and PD-L1 by bintrafusp alfa promotes survival in preclinical ovarian cancer models by promoting T effector and NK cell responses | British Journal of Cancer - Nature
Harnessing Microbial Effectors for Macrophage-Mediated Drug Delivery - ACS Publications
Effector Therapeutics Inc (EFTR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.91%
1.17%
자본화:
|
볼륨(24시간):